Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Neurocrine licenses up to four Voyager neuro programs in $1.9bn collaboration; deal restructured

Executive Summary

Neurocrine Biosciences Inc. and Voyager Therapeutics Inc. will collaborate on the development of up to four Voyager neurological disease candidates. The deal includes two adeno-associated virus (AAV) potential gene therapies--VYAADC, a DOPA decarboxylase stimulant in Phase II for Parkinson’s disease (PD) and preclinical VYFXN01, a frataxin agonist for Friedreich’s ataxia (FA)--plus two yet-to-be-determined discovery programs.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies